| Jul 29 |
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
|
| Jul 26 |
Morgan Stanley starts CervoMed at overweight, cites upcoming data
|
| Jul 17 |
CervoMed to Participate in the Emerging Growth Conference
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
| Jul 11 |
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
|
| Jun 29 |
CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans
|
| May 31 |
CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…
|
